	i				Docket Number (Optional) 021286/027 633		Application Number	844,684	
	INFO	RMATION DISCLOSURE			Applicant(s) Mikayama, et al.				
		(Use several sheets) paces of	ig.		Filling Date April 27, 2001		Group Art Unit	1645	644
		20 200	Frice	U.S. PAT	ENT DOCUMENTS				
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO	
M		5,677,165	10/14/97	de Boer	, et al.	,		May 28,	
		5,786,456	7/28/98	Ledbett	er, et al.			Sept. 20	, 1993
	_	5,801,227	9/1/98	Fanslov	v, III, et al.			Sept. 8,	1995
W		5,874,082	2/23/99	de Boer				Feb. 23,	1996
<u> </u>									
						·			•
	ļ. —								

	<u> </u>	<u> </u>	<u> </u>	FOREIG	N PATENT DOCUMENTS			l	
	REF	DOCUMENT NUMBER	DATE	-	COUNTRY	CLASS	SUBCLASS	Trans YES	dation NO
W		WO 99/42075	08/26/99	PCT	-			_/	·
		<u> </u>							
				-					
	<u> </u>								
							-		
	L	1	<u></u>	OTHER	DOCUMENTS (Including A	uthor, Title,	Date, Pertinent Pa	iges, Etc.)	<u></u>
M	<i>-</i>	Tomizuka, et al., "Doub containing Ig heavey and	le trans-chromos d kappa loci and	omic mice expression	: Maintenance of two indiv of fully human antibodies'	idual huma ', PNAS, Ja	n chromosome i n. 18, 2000, Vol	Fragments . 97, no. 2.	
W	7	Schoenberger, et al., "T June 4, 1998.	-cell help for cyto	otoxic T ly	mphocytes is mediated by C	CD40-CD40	L interactions",	, Nature, V	ol. 393,
EXAMINE	:R	PHULPGSON	102-6/	2/02	DATE CONSIDERED				
		al if citation considered, whether	or not citation is in	conforman	ce with MPEP Section 609; Di	raw line thro	ugh citation if no	in conform	ance and
not conside	ered. In	clude copy of this form with next	communication to a	applicant.					

.,,			Docket Number (Optional) 021286/027 633	Application Number 09/844,684
INFO		TION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant(s) Mikayama, et al.	
	•	••••••••••••••••••••••••••••••••••••••	Filing Date 4/27/01	Group Art Unit 1649 1644
*EXAMINER		OTHER DOCUMENTS (Including Author, Title	e, Date, Pertinent Pages, Etc.)	
PO PE	3Cias	Stamenkovic, et al., "A B-lymphocyte activation mo in carcinomas", The EMBO Journal, Vol. 8, no. 5,	plecule related to the nerve growth fac pp. 1403-1410, 1989.	tor receptor and inuced by cytokines
PERTA TPI		Clark, et al., "CDw40 and BLCa-specific monocion Signals to human B lymphocytes*", Eur. J. Immuno	al antibodies detect two distinct molecol., 1988, 18: 451-457.	ules which transmit progression
		Ledbetter, et al., "Augmentation of Normal and Ma Antigen BP50 (CDW40), The Journal of Immunolo	alignant B Cell Proliferation by Mono- gy, Vol. 138, pp. 788-794, No. 3, Febru	clonal Antibody to the B Cell-Specific lary 1, 1987.
		Clark, et al., "Activation of human B cells mediated Bp50", Proc. Natl. Acad. Sci. USA, Vol. 83, pp. 449	through two distinct cell surface diffe 4-4498, June 1986.	erentiation antigens, Bp35 and
OC		Paulie, et al., "A p50 surface antigen restricted to h Immunology Immunother, (1985), 20: 23-28.	uman urinary bladder carcinomas and	i B lymphocytes", Cancer
				. ,
	· · · ·			
EXAMINER	G.	mber 6/13/03	DATE CONSIDERED	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1			-								·			
		149 (modified) artment of Commerce	10		7	•		Atty. M Dkt. No.	#		Client	t Ref.		
(PW FC	RM PA	AT-1449) d Trademark Office		6 201	2									
'		13	A		*				21286-027633	0 .				
INFOR	TAM	ION DISCLOSUR	E A	DEM	FNT				Mikayama, T.,					
BY AP			(L OH		#EITT			, , , , , , , , , , , , , , , , , , , ,						
								Appln. No.:	09/844,684					
					_			Filing Date:	April 27, 2001					
Date: D	ecem)	ber 9, 2002	Page	1	of	1	<u> </u>		Philip Gambel		up Art U			
U.S. P	ATEN	DOCUMENTS		44							5,		7	<u> </u>
Examin	١	Document		Date		Name				Class			Filing	
er's Initials*	,]	Number		MM/\	YYY	(Family	Name	of First Inver	ntor)		Clas	5	Date (if approp	riate)
N	AR	5,786,456		07/19	98	Ledbette	er et a			530	388.	73	09/20/93	
1	BR	6,004,552		12/19		de Boer		••		424	144.		06/05/95	5
	CR	6,051,228		04/20	000	Aruffo, e				424	144.	1	02/19/98	3
	DR					<u> </u>				<u> </u>			<u> </u>	
	ER	 		ļ		<u> </u>							 	
-	FR	<u> </u>					 -			-	-		 	
unggan ning	GR	United States of the States of	ar emaile	. Nis. (195)	aerant.		Maria de la		ineliya dinyala ak		ru-b		Topolo	
FORE	GNIRA	TENT DOCUMEN Document	Date		Coun	try	Inve	ntor Name		binini.	English Abstract		Translat Readily Available	
		Number	MMY	YYY		•					F	1	Factors	<u> </u>
	1.5	WO 005504044	40.00		POT		0:	-II. Olav B	0400145/00		Enclosed	No	Enclose	No
	HR	WO 00/75348A1	12/20	00	PCT		et al.	all, Clay B.,	C12N 15/63			╁	 	十
	IR	WO 01/83755 A2	11/20	01	РСТ		Mika al.	yama, T., et	C12N 15/13					I
1	JR	WO 01/83755 A3			PCT		Mika al.	yama, T., et	C12N 15/13		_	_		_
M	KR	WO 02/28904 A2	04/20	02	PCT		Chu	K., et al.	C07K 16/28					<u> </u>
	LR		ļ <u>.</u>		<u> </u>		╄					╄-	 	╄
	MR				-									╀
	NR OR				 		+					\vdash	+	+
	PR	 	 		 		+		- 			+	 	+-
	QR				1		+					1	†	✝
OTHER		uding in this order A	Author.	Title.	Period	lical Nam	e. Dat	e. Pertinent I	Pages, etc.)			Ť	† .	T
	RR		•	,				•					<u> L</u>	L
	SR													
	TR											<u> </u>	 	<u> </u>
<u> </u>	UR					•						igapha	 	+
	VR					· 						╂	 	+-
	WR	1										<u> </u>	<u> </u>	
Examin	er							Date Consid	dered:					

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Gamose 6 (13/03

To	ÃÚ.S. I N FOR	Depai M PA	49 (modified) tment of Commerce T-1449) Trademark Office	1	AR 2 4	2003	VC58		Atty. Dkt. No.	M# 021	286-0276339		Clien	t Ref.			
	FORM		ON DISCLOSUR	E ST	ATEN	ENT			Applicant	t: Mil	kayama, T., e	t al.					
_		_, .							Appin. No	o.: 0	9/844,684				<u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>		\dashv
						_		_	Filing Da	te: A	oril 27, 2001						
Da	te: Ma	rch 2	20, 2003	Page	1	of	3	<u>· </u>	Examine	r. Phi	lip Gambel	Gro	up Art U	nit: 1	644		
U.S	S. PAT	ENT	DOCUMENTS		<u></u>	, (' ' '		· · ·		×			. ` .			÷.;	<u> </u>
er	amin s tials*		Document Number		Date MM/Y	YYY	Name (Family	Name	of First In	vento	r)	Class	Sub Clas	s	Filin Date (if app	•	ite)
11:11	uais	AR													,		7
		BR					<u> </u>						_				\dashv
FC		_	TENT DOCUMEN	TS :		nają.		. K.	4. 8. 3²⁷. 1. 2	: :: 4	, profession		English		Trans	slation	7
			Document Number	Date MM/Y		Coun	try	Inver	ntor Name		0		Abstract		Read Avail		
													Enclosed	No	Enclo	se N	ło
M	9	CR	WO 91/09115	06/19	91	PCT		Band	hereau				Υ	<u> </u>			
	*	DR	WO 96/33735	10/19	96	PCT		Kuch	erlapati				Υ	<u> </u>		\bot	_
		ER	WO 96/34096	10/19	96	PCT	• .	Kuch	erlapati_				Υ	10 C	<u> </u>	_	- C 0
		FR	WO 99/61051	12/19	99	PCT		Sega	al				Υ	5		3	
		GR	WO 00/00156	01/20	00	PCT		Wad	e				Υ	 	Ě.	70	
		HR	WO 00/75348 A1	12/20	00	PCT		Sieg	all				Υ	<u> </u>	<u> </u>	-	_
		IR	WO 01/24823	04/20	01	PCT		Ketin					Υ	چ	0	203	_<
		JR	WO 01/56603	08/20	01	PCT		Thor	nas				Υ	3	0601000	<u> </u>	11
\dashv		KR	WO 02/28904	04/20		PCT		Chu					Υ .		8	\dashv	_
4			EP 0945 465 A1	09/19		EP		De B					Y	<u> </u>		-	4
		-	EP 0972 445 A1			EP		Tom					Y	 	<u> </u>	+	=
O	THER		ding in this order A Kwekkeboom, et a CD3 mAb can be CD40-CD40 ligand	al., "He enhan	lper el	ffector co-sti	function mulatory	of hun	nan T cells s and is p	s stim artiall	ulated by ant y dependent		Y				
		OR	Hasbold, et al., "C following stimulation 1040-1051.	ell divi on by C	sion no CD40 I	umber igand	regulate and IL-4	s IgG1 ," <u>Eur</u>	and IgE s J. Immund	switch ol. (19	ing of B cells 198), Vol. 28,	рр.	Y		ō		
		PR	Pound, et al., "Min suppression of ap homotyic adhesion 20.	optosis	contr	ast wit	th those	for proi	motion of	the c	ell cycle and		Y				
		QR	Francisco, et al., ". Antibody SGN-14,										Y				
		RR	Romano, et al., "T B Chronic Lympho 990-995.	riggeri ocytic L	ng of (euker	CD40 / nia Ce	Antigen I	nhibits <u>od,</u> (Au	Fludarabi gust 1, 19	ine-In 998) \	duced Aoptos 'ol. 98, No. 3,	sis in pp.	Y				
	h	SR	Hirano, et al., "Inh Recombinant Hun 3007.									999-	Y				

Gamge 6/13/07

			Construction & Anti-Cogo BDI-G185				
	plu To a		Francisco, et al., "Constitution, Expression, and Characterization of 11-G28-5 sFv, a Single-chain Anti-CD4 immunotoxin Containing the Ribosome –inectivating Protein Bryodin 1," Journal of Biological Chemistry, (Sept. 26, 1997), Vol. 272, No. 39, pp. 24165-24169.	- in a	cti	ni ta v	5
Was Name	4 2023	(F)	Maxwell, et al., "Contrasting the Roles of Costimulation and the Natural Adjuvant Lipopolysaccharide During the Induction of T Cell Immunity," <u>J. Immunol.</u> , (May 1, 2002), Vol. 168, No. 9, pp. 4372-4381.	Y			
e de la companya de l	ADIRA	/	Simonsson, et al., "Single, Antigen-Specific B Cells Used to Generate Fab Fragments Using CD40-Mediated Amplification or Direct PCR Cloning," BioTechniques, (1995), Vol. 18, No. 5, pp. 862-869.	Y			
	V	- 1	Dullforce, et al., "Enhancement of T cell-independent immune responses <i>in vivo</i> by CD 40 antibodies," Nature Medicine, (Jan. 1998), Vol. 4, No. 1, pp.88 – 91.	Y			
	×		Erickson, et al., "Short-circuiting long-lived humoral immunity by the heightened engagement of CD40," The J. of Clinical Investigation, (March, 2002), Vol. 109, No. 5, pp. 613-620.	Y	-ii		
	Y		Murphy, et al., "Antibodies to CD40 Prevent Epstein-Barr Virus- Mediated Human B-Cell Lymphomagenesis in Severe Combined Immune Deficient Mice Given Human Peripheral Blood Lymphocytes," <u>Blood</u> , (September 1, 1995), Vol. 86, No. 5, pp. 1946-1953.	Y	ECH CENT	MAR 9	RECE
	Z		Funakoshi, et al., "Differential In Vitro and In Vivo Antintumor Effects Mediated by Anit-CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-Cell Lyphomas," J. of Immunology, (1996) Vol. 19, No. 2, pp. 93-101.	Y	ER 1600	5 200	IVE
	A	ΔR	Schwabe, et al., "Modulation of Soluble CD40 Ligand Bioactivity with Anti-CD40 Antibodies," <u>Hybridoma</u> , (1997), Vol. 16, No. 13, pp. 217-226.	Y	2990		P
	В		Funakoshi, et al., "Inhibition of Human B-Cell Lymphoma Growth by CD40 Stimulation," Blood, (May 15, 1994), Vol. 83, No. 10, pp. 2787-2794.	Y			П
	C		Rolink, et al., "The SCID but Not the RAG-2 Gene Product Is Required for Sμ-Sε Heavy Chain Class Switching," Immunity, (October, 1996) Vol. 5, pp. 319-330.	Y			П
	C	DR	Kwekkeboom, et al., "CD40 plays and essential role in the activation of human B cells by murine EL4B5 cells," Immunology, (1993), Vol. 79, pp. 439-444.	Y			
	E		Zhou, et al., "An Agonist Anti-Human CD40 Monoclonal Antibody that Induces Dendritic Cell Formation and Maturation and Inhibits Proliferation of a Myeloma Cell Line," Hybridoma, Vol. 18, No. 6, 1999, pp. 471-478.	Y			
	F		Heath, et al., "Monoclonal antibodies to murine CD40 define two distinct functional epitopes," Eur. J. Immunology, (1994) Vol. 24, pp. 1828-1834.	Υ			
	0		Mazzei, et al., "Recombinant Soluble Trimeric CD40 Ligand Is Biologically Active," Journal of Biological Chemistry, (March 31, 1995), Vol. 270, No. 13, pp. 7025-7028.	Υ			
	F		Hasbold, et al., "Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies," <u>Eur. J. Immunology</u> ., (1994) Vol. 24, pp. 1835-1842.	Y		_	
	11	IR	Weng, et al., "Human Anti-CD40 Antagonistic Antibodies Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma," Program of the 43 rd Annual Meeting of The American Society of Hematology, (December 7-11, 2001), Abstract No. 1947, page 466a.	~			
	J		Ledbetter, et al., "Agonistic Activity of a CD40-Specific Single-Chain Fv Constructed from the Variable Regions of mAb G28-5," <u>Critical Reviews in Immunology</u> , (1997), Vol. 17, pp. 427-435.	Y			
	K		de Boer, et al., "Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins," <u>Journal of Immunological Methods</u> , (1992) Vol. 152, pp. 15-23.	Y			
			Karlsson, et al., "Selection of human single chain antibodies against CD-40," Immunology Letters, Vol. 73, Nos. 2,3, Abstract No. 358.	Υ			
	1 A		Sotomayor, et al., "Conversion of tumor-specific CD4 T-cell tolerance to T-cell priming through in vivo ligation of CD40," Nature, (July, 1999), Vol. 5, No. 7, pp. 780-787.	Y			

Gamosa 6/13/03

		701174 1070		
R	NNR	Diehl, et al., "CD40 activation in vivo overcomes peptide-induced perioral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy," No. 7, pp. 774-779. Tolerance and	Y	
(FL	OOR	Schoenberger, et al., "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions," Nature, (June 4, 1998), Vol. 393, pp.480-483.	Y	
2 4 200	8 341	van Mierto, et al. "CD40 stimulation leads to effective therapy of CD40-tumors through induction of strong systemic cytotoxic T lymphocyte immunity," <u>PNAS</u> , (April 16, 2002) Vol. 99, No. 8, pp. 5561-5566.	Y	
E TO DIAM	ook	An, et al., "Ligation of CD40 Potentiates Fas-Mediated Activation of the Cysteine Protease CPP32, Cleavage of Its Death Substrate PARP, and Apoptosis in Ramos – Burkitt Lymphoma B Cells," Cellular Immunology, (1997) Vol. 181, pp. 139-152.	Y	
		Barr, et al., "Functional activity of CD40 antibodies correlates to the position of binding relative to CD154," Immunology, (2001) Vol. 102, pp. 39-43.	Y	
		Baccam, et al., "Membrance-bound CD154, but not CD40-specific antibody, mediates NF-xB-independent IL-6 production in B cells," <u>Er. J. Immunol.</u> , (1999), Vol. 29, pp. 3855-3866.	Y	
		Kedl, et al., "CD40 stimulation accelerates deletion of tumor specific CD8+ T cells in the absence of tumor-antigen vaccination," <u>PNAS</u> , (September 11, 2001) Vol. 98, No. 19, pp. 10811-10816.	Y	
		Tomizuka, et al., "Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing-lg-heavy and k loci and expression of fully human antibodies," PNAS, (January 18, 2000) Vol. 97, No. 2, pp. 722-727.	Y	
M	WR	Boon, et al., "Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys," Toxicology, (2002), Vol. 174, pp. 53-65.	Y	
	ww	R		
	XXR			
	YYR			
	ZZR			
Examiner		Date Considered:		

Gamber 6/12/03

in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

MAR & 5 2003

TECH CENTER 1800/2800